Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|December 15, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-04-2017
- Volume 12
- Issue 1
DuPont Receives Grant from Bill & Melinda Gates Foundation
Author(s)Pharmaceutical Technology Editors
DuPont received a grant from the Bill & Melinda Gates Foundation to produce pharmaceutical proteins.
Advertisement
On Dec. 15, 2016, DuPont Industrial Biosciences announced the receipt of a grant from the Bill & Melinda Gates Foundation to support a research project aimed at creating new production systems to enable affordable, protein-based biologic medications. Through a grant from the Bill & Melinda Gates Foundation, DuPont will apply its capabilities in the areas of protein engineering, pathway engineering, and cell factories to the field of protein drugs. When applied to pharmaceutical protein production, this approach has the potential to enable rapid scale-up and lower costs at high volumes, making protein drugs such as monoclonal antibodies potentially suitable for infectious diseases, effectively managing outbreaks and providing affordable supply to people around the world.
The Bill & Melinda Gates Foundation has invested in drug discovery research through a variety of mechanisms. In a time when public-funded research is diminishing, companies such as DuPont are engaging in new ways with stakeholders across the public and private sectors to tackle large societal challenges, Dupont said in a press release.
Source: DuPont Industrial Biosciences
Articles in this issue
almost 10 years ago
New Catalysts Enable Cross-Coupling Reactionsalmost 10 years ago
Outsourced Testing and Manufacturing Support Biosmiliar Projectsalmost 10 years ago
AGC Asahi Glass Acquires CMC Biologicsalmost 10 years ago
Three Novasep Facilities Pass FDA Inspectionalmost 10 years ago
Vetter Begins Manufacturing on Clinical Syringe Filling Linealmost 10 years ago
Aurinia and Lonza Enter into Manufacturing Agreementalmost 10 years ago
Fluor Builds Diabetes API Manufacturing Facility for Novo Nordiskalmost 10 years ago
Lonza to Acquire CapsugelAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement